Oxaliplatin in Gastric Cancer
To determine the objective response to oxaliplatin/5FU/leucovorin combination chemotherapy in patients with advanced unresectable or metastatic gastric cancer.
Stomach Neoplasms
DRUG: Oxaliplatin
To evaluate response rate according to RECIST criteria|To evaluate the progression-free survival in the ITT population
To evaluate the overall survival in the ITT population|To investigate safety using NCI-CTC criteria version 2
To determine the objective response to oxaliplatin/5FU/leucovorin combination chemotherapy in patients with advanced unresectable or metastatic gastric cancer.